U.S. Healthcare Services Stock News

Despite an already strong run, Sunrun Inc. ( NASDAQ:RUN ) shares have been powering on, with a gain of 27% in the last...

With a price-to-earnings (or "P/E") ratio of 23.5x Middlesex Water Company ( NASDAQ:MSEX ) may be sending bearish...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Novocure recently announced that final results from the pivotal Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting and published simultaneously in a leading clinical journal. This milestone provides critical new data on TTFields therapy in a significant and challenging cancer indication, highlighting progress in expanding the clinical...

Arch Capital Group (ACGL) shares have seen modest movement this week, with the stock currently trading around $92. Investors are recalibrating their outlook as a result of steady revenue and net income growth, fueling curiosity about where ACGL could head next. See our latest analysis for Arch Capital Group. After a rocky year, Arch Capital Group’s 1-year total shareholder return is still in the red at -14.84%. However, the stock has climbed roughly 5% over the past three months and has...

PayPal Holdings (PYPL) shares have bounced around over the past month, rising more than 11%. Investors are watching the payments company closely as they weigh recent performance alongside longer-term trends in the financial technology industry. See our latest analysis for PayPal Holdings. Despite a recent 12% jump in the share price over the past month, PayPal Holdings is still working to reverse a longer-term trend that has seen momentum fade, with a 1-year total shareholder return of -4%...

Haemonetics (HAE) is attracting attention following a wave of analyst downgrades and lowered growth forecasts. This is driven by mounting concerns about tougher market conditions and an expected dip in sales over the next year. See our latest analysis for Haemonetics. After a rough quarter, Haemonetics’ share price has slid to $50.15. The stock has experienced a recent 7-day rebound but is still down significantly with a 30-day share price return of -7.54% and a steep 1-year total shareholder...

In the past week, reports have surfaced that Oracle's rapidly growing AI cloud server business, despite securing sizable contracts and increasing revenue, has been operating with much thinner profit margins than anticipated due to high hardware costs and aggressive customer pricing. This revelation prompted investors to question the long-term profitability and sustainability of Oracle's AI infrastructure push, highlighting concerns about the company's ability to balance strong top-line...

Helen of Troy (HELE) remains in the red, with losses worsening at an annualized rate of 42% over the last five years. Looking ahead, forecasts point to continued unprofitability for at least the next three years, while revenue is expected to edge up just 1% annually, which is below the US market’s 9.9% average. Despite this sluggish outlook, HELE stands out for its discounted Price-to-Sales Ratio of 0.3x, significantly lower than both its industry and peer averages. This could attract...

AMETEK (AME) continues to draw attention from investors as recent analyst coverage points to the company’s ongoing streak of topping earnings estimates. This consistent performance has helped shape positive expectations for its next quarterly results. See our latest analysis for AMETEK. Even with the broader market facing some turbulence, AMETEK’s latest share price of $183.31 keeps it firmly on investors’ radar. Momentum has cooled slightly in recent weeks, but the real story is its 9.25%...

Trying to decide what to do with JPMorgan Chase stock lately? You are not alone. With a last close at $305.53 and a five-year return of 242.0%, investors have plenty of reasons to pay close attention. While the past week saw JPMorgan dip by 0.7%, this barely dents a run that had the stock up 27.3% so far this year and an eye-catching 46.6% over the past twelve months. In other words, short-term noise aside, JPMorgan has been a winner for long-term holders. There is more to this story than...

In recent days, Bank of America downgraded Sonoco Products to neutral, citing sluggish demand trends in both consumer and industrial packaging markets, while UBS also lowered its price target and maintained a cautious tone. These shifts in analyst sentiment have focused investor attention on demand headwinds and the lack of immediate earnings upside from Sonoco's recent portfolio changes. We'll examine how these demand concerns and analyst downgrades may influence Sonoco's narrative around...

UnitedHealth Group (UNH) shares have been showing some interesting movement lately, prompting investors to take a closer look at the company’s valuation. With recent price swings, many are weighing long-term fundamentals in comparison to short-term volatility. See our latest analysis for UnitedHealth Group. After a tough start to the year, UnitedHealth Group’s 20.9% share price rebound over the past 90 days signals a shift in momentum. Its 1-year total shareholder return is still down...

On October 3, 2025, Oruka Therapeutics (ORKA) announced a series of shelf registrations for multiple securities, including common and preferred stock, depositary shares, and warrants. The company also filed a $200 million follow-on equity offering. See our latest analysis for Oruka Therapeutics. It’s been a dramatic stretch for Oruka Therapeutics, with momentum really catching fire after the latest capital raise announcements. The stock notched a 33% 7-day share price return and is up 59% for...

Recent analysis highlights that Federal Signal has expanded its operating margin by 4.4 percentage points over the past five years, achieved annual earnings per share growth of 28.5% over two years, and improved its free cash flow margin by 4.1 percentage points. This operational progress indicates that Federal Signal is becoming more efficient and profitable, positioning itself with increased resources to pursue growth opportunities or shareholder returns. We'll examine how Federal Signal's...

Thinking about what to do with Campbell's stock right now? You are definitely not alone. With the share price closing at $29.89 recently, Campbell's has caught the eye of many investors wondering whether the old-school staple just got stuck in the pantry or if there is value waiting for discovery. Over the past week, shares dipped 5.4%, carving out a notable drop; stretch that timeline to a month and the slide turns steeper at -11.4%. Year-to-date, the stock is down an eye-opening 28.9%, and...

If you have been keeping an eye on NIO, you already know that this stock comes with a healthy dose of excitement and risk. The past year alone saw NIO climb nearly 20%, and if you had jumped on board since January, your gains would be a striking 64%. Yet, this is not the whole story. Zoom out to the last three years, and NIO is still down 41.6%, and over the past five years, the returns sink further into negative territory at -73.4%. The short term has been a bit shaky too, with a -5.4% dip...

Thinking about what to do with Ferrari stock right now? You are not alone. The iconic Italian automaker has had a bumpy ride recently, sliding nearly 19% in just the past week and more than 15% over the last 30 days. Even year-to-date, Ferrari is down a modest 2.2%, and over the last 12 months it has slipped 9.4%. However, if you step back a bit further, the outlook quickly shifts. Shares are up a remarkable 126.8% over three years and an equally impressive 124.3% over five years. Such mixed...

In recent days, Udemy (NASDAQ: UDMY) experienced market adjustments as investors focused attention on the company’s operational performance and how it manages its online learning platform. This increased scrutiny of platform functionality and user engagement signals a heightened market focus on the drivers of digital learning sector trends. We'll explore how this intensified attention on Udemy’s platform management may influence its investment narrative and earnings outlook. Uncover the...

Ryan Specialty Holdings has named Stephen P. Keogh and Brendan M. Mulshine as Co-Presidents, stepping in for Jeremiah Bickham, who now serves as a strategic advisor. This executive change arrives as the company navigates ongoing organizational challenges. See our latest analysis for Ryan Specialty Holdings. Recent leadership changes are grabbing headlines, but the market has been less enthusiastic. Ryan Specialty Holdings’ share price slipped 4.6% in the past day and is down 11.2%...

Biomea Fusion (BMEA) has completed a $25 million equity offering following the release of data from its Phase II COVALENT-111 trial. The study showed sustained HbA1c reduction in type 2 diabetes patients. See our latest analysis for Biomea Fusion. Biomea Fusion’s stock has been notably volatile. Shares initially jumped on the back of encouraging Phase II clinical data, but quickly reversed and dropped sharply after the $25 million equity offering was announced. With the latest share price at...

Regal Rexnord Corporation recently announced it will release its third quarter 2025 financial results after market close on October 29, 2025, with a conference call to follow the next morning. Investor enthusiasm has been fueled by analyst upgrades and strong positioning in energy-efficient and automation markets, as well as recent acquisitions and a growing backlog. We'll explore how renewed analyst optimism and Regal Rexnord's expansion in energy-efficient solutions affect the company's...

In recent days, BlackSky Technology reached a new 52-week high after securing major government and international contracts, including a seven-figure agreement with HEO and a two-year Gen-3 early access deal with an international client. This milestone spotlights BlackSky's growing presence in geospatial intelligence and the rising global demand for its advanced Earth observation analytics. We'll explore how winning significant international contracts could reshape BlackSky's investment...

In recent news, the District Court for the District of Delaware ruled that claims in the 11,634,752 patent, previously held by Scale Biosciences and now part of 10x Genomics, were invalid due to lack of written description and enablement. This legal decision may have implications for 10x Genomics’ intellectual property portfolio and competitive landscape in the single cell and spatial analysis market. This outcome signals a potential shift for 10x Genomics, as questions around patent...